Endo to distribute bivalirudin injection in ready-to-use vials

Endo will commercialize the product through its Par sterile products business and expects to begin shipping in summer 2023.
Sandra Levy
Senior Editor
Levy

Endo’s subsidiary Endo Ventures has reached an agreement with Maia Pharmaceuticals to distribute bivalirudin injection in a ready-to-use 250 mg/50 ml single-use vial in the United States. Endo will commercialize the product through its Par Sterile Products business and expects to begin shipping in summer 2023.

"Hospital providers have told us what they need—ready-to-use medications that allow them to focus on patients rather than preparation," said Scott Sims, senior vice president and general manager of injectable solutions and generics at Endo. "Through this partnership with Maia Pharmaceuticals, we are proud to answer that call with the only ready-to-use liquid format of bivalirudin."

[Read more: Par launches generic Pylera]

"Like Endo, Maia is laser-focused on delivering meaningful solutions to support healthcare providers as they deliver quality patient care," said Brian Cooney, senior director of corporate development at Maia Pharmaceuticals. "We are pleased to partner with Endo to provide ready-to-use bivalirudin, which requires no reconstitution, no dilution and no mixing."

[Read more: Par launches authorized generic of Noxafil]

Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care, the company said. 

X
This ad will auto-close in 10 seconds